Shifting to non-viral in vivo therapies to enhance global patient access to genetic medicines

David McCall, Senior Editor of BioInsights, talks to Hari Pujar, Chief Operating Officer, Tessera Therapeutics and Operating Partner, Flagship Pioneering, about current trends in the cell and gene therapy field aimed at addressing long-standing issues of manufacturing scalability, complexity, and high cost of goods.

Please enter your email to access content Read now